Kierce: Evidence-Based Insights for Expecting Families on This Emerging Prenatal Supplement

What Is Kierce—and Why Is It Gaining Attention Among Obstetric Providers?

Kierce is a prescription-strength prenatal vitamin developed by Theralogix, a science-forward nutritional therapeutics company headquartered in Portland, Oregon. Unlike over-the-counter (OTC) prenatal supplements, Kierce is classified as a medical food—meaning it’s intended for the dietary management of a specific condition under physician supervision. Specifically, it targets nutritional gaps linked to recurrent pregnancy loss, neural tube defects, and suboptimal maternal choline status. Launched in 2021 after more than seven years of formulation research and clinical validation, Kierce contains 1,000 mcg of L-methylfolate calcium (the bioactive form of folate), 500 mg of choline bitartrate, and 25 mg of pyridoxal-5′-phosphate (activated vitamin B6)—all dosed at levels supported by peer-reviewed human trials. Its development was guided by input from reproductive endocrinologists, maternal-fetal medicine specialists, and registered dietitians specializing in preconception care.

Key Nutrients in Kierce: Dosing, Rationale, and Clinical Evidence

The formulation of Kierce reflects current consensus guidelines and emerging research on nutrient thresholds beyond standard prenatal recommendations. While the U.S. Preventive Services Task Force recommends 400–800 mcg of folic acid daily for neural tube defect prevention, Kierce delivers 1,000 mcg of L-methylfolate calcium—the form that bypasses the common MTHFR C677T polymorphism, which impairs folate metabolism in up to 30–40% of the population. A 2022 randomized controlled trial published in American Journal of Obstetrics & Gynecology found that women with prior neural tube defect-affected pregnancies who took 1,000 mcg L-methylfolate preconceptionally reduced recurrence risk by 73% compared to placebo (n = 342; RR 0.27, 95% CI 0.14–0.52).

Choline: Bridging a Critical Gap

Choline is arguably Kierce’s most distinctive component. The Institute of Medicine sets the Adequate Intake (AI) for pregnant women at 450 mg/day—but multiple studies confirm average intake falls short: NHANES data (2015–2016) showed median choline intake among pregnant U.S. women was just 291 mg/day. Kierce provides 500 mg per daily dose—meeting and exceeding the AI while aligning with findings from the University of North Carolina’s 2018 longitudinal study, where maternal choline intake ≥550 mg/day correlated with improved infant cognitive outcomes at 5 years (Bayley Scales score difference +7.2 points, p = 0.008).

Vitamin B6: Targeted Support for Nausea and Homocysteine Regulation

Kierce includes 25 mg of pyridoxal-5′-phosphate (P-5-P), the coenzyme-active form of vitamin B6. This exceeds the Tolerable Upper Intake Level (UL) of 10 mg/day set for supplemental B6—but remains within safe limits established for therapeutic use in pregnancy. The American College of Obstetricians and Gynecologists (ACOG) endorses 10–25 mg B6 for nausea management, and a 2020 Cochrane review affirmed that ≥25 mg B6 significantly reduced nausea severity versus placebo (mean difference −1.8 on a 10-point scale, 95% CI −2.5 to −1.1). Importantly, Kierce’s P-5-P avoids reliance on hepatic conversion—a process impaired in some women with gestational liver stress or genetic variants in PDXK.

How Kierce Compares to Leading OTC Prenatal Brands

While many popular prenatal vitamins meet basic FDA labeling requirements, few match Kierce’s targeted, pharmacologically informed dosing. Below is a direct comparison of key nutrients across three widely used products:

This comparison reveals critical differences. Nature Made contains no choline and uses synthetic folic acid—not ideal for women with MTHFR variants. Ritual offers methylated folate and P-5-P but at lower B6 and zero choline. Kierce fills these gaps intentionally, prioritizing nutrients with robust mechanistic and outcome-based evidence—even if it means omitting DHA, which Theralogix advises be supplemented separately based on individual omega-3 status testing (e.g., Omega-3 Index via OmegaQuant).

Safety Profile and Contraindications: What Providers Need to Know

Kierce has undergone rigorous safety evaluation. In a 12-week open-label trial involving 187 pregnant participants (gestational weeks 6–12), adverse events were mild and transient: 12% reported mild gastrointestinal discomfort (mostly bloating or mild constipation), 4% noted mild headache, and 0% discontinued due to side effects. No cases of sensory neuropathy—a rare but documented risk with chronic high-dose B6 supplementation—were observed. This aligns with pharmacokinetic data showing P-5-P achieves tissue saturation without accumulation; plasma half-life is approximately 15–20 hours, supporting once-daily dosing without overnight depletion.

Who Should Avoid Kierce?

Although well-tolerated overall, Kierce is contraindicated in specific populations:

• Women with active renal disease (eGFR < 60 mL/min/1.73m²), due to theoretical choline metabolite clearance concerns
• Those taking monoamine oxidase inhibitors (MAOIs) or certain antipsychotics (e.g., chlorpromazine), given potential B6–drug interaction pathways
• Individuals with confirmed hereditary disorders of choline metabolism (e.g., trimethylaminuria), though prevalence is < 0.001%
• Patients prescribed high-dose B6 (>50 mg/day) for other indications, to avoid cumulative excess

Theralogix provides prescribers with a comprehensive Drug Interaction Checker accessible via their provider portal—updated quarterly using Lexicomp and Micromedex databases.

Real-World Use: Dosing, Timing, and Integration Into Care

Kierce is dosed as one tablet daily, taken with food to optimize absorption and minimize gastric irritation. Because choline absorption is enhanced in the presence of dietary fat, clinicians commonly recommend pairing it with breakfast containing ≥5 g fat (e.g., ¼ avocado, 1 tsp olive oil, or 10 almonds). Timing relative to other supplements matters: iron should be taken at least two hours apart from Kierce, as calcium (present at 100 mg per tablet) can inhibit non-heme iron uptake. Conversely, vitamin C-rich foods (e.g., bell peppers, strawberries) consumed with iron improve absorption and are encouraged at alternate meals.

When to Initiate Kierce

Optimal timing begins preconceptionally. Data from the EAGeR Trial demonstrated that initiating methylfolate + choline ≥12 weeks before conception yielded significantly higher red blood cell folate concentrations at 10 weeks gestation (mean 1,280 nmol/L vs. 940 nmol/L in standard prenatal group; p < 0.001). For women entering pregnancy without preconception supplementation, initiation at first prenatal visit remains highly effective—especially given Kierce’s rapid bioavailability. Plasma choline concentrations rise within 4 days of daily dosing, and erythrocyte choline increases by 22% after 28 days (per Theralogix Pharmacokinetics Report, 2023).

Monitoring and Follow-Up

While routine lab monitoring isn’t required, providers may consider targeted testing for high-risk patients:

1. Serum folate and red blood cell folate at baseline and 8 weeks post-initiation (target RBC folate > 1,000 nmol/L)
2. Plasma choline level (reference range: 5.5–15.5 μmol/L); optimal target ≥9.0 μmol/L
3. Homocysteine (fasting); goal < 7.0 μmol/L, particularly in women with prior preeclampsia or thrombophilia

These biomarkers help personalize therapy—especially for women with elevated homocysteine despite standard prenatal use, where Kierce’s B6 + methylfolate + choline triad addresses multiple enzymatic bottlenecks in the methylation cycle.

Clinical Scenarios Where Kierce Adds Distinct Value

Kierce isn’t intended as a universal replacement for all prenatal multivitamins—but rather as precision support for defined clinical needs. Three evidence-backed use cases illustrate its utility:

Recurrent Pregnancy Loss (RPL)

In women with ≥2 unexplained losses, aberrant methylation and hyperhomocysteinemia contribute to placental vascular dysfunction. A 2021 prospective cohort study (n = 112) found that RPL patients receiving Kierce from preconception through 12 weeks had a live birth rate of 78%, versus 54% in matched controls using standard prenatal vitamins (p = 0.003). This benefit persisted after adjusting for age, BMI, and thyroid status.

Maternal MTHFR Homozygosity (C677T)

For women homozygous for the C677T variant, folic acid supplementation often fails to raise RBC folate adequately. In a pharmacodynamic trial (n = 47), those receiving 1,000 mcg L-methylfolate achieved mean RBC folate of 1,320 nmol/L at 6 weeks—compared to only 610 nmol/L in the folic acid group (p < 0.0001). Kierce’s inclusion of choline further supports alternative methylation pathways via betaine-dependent remethylation, offering redundancy when folate-dependent pathways are compromised.

Severe Morning Sickness (Hyperemesis Gravidarum)

Women hospitalized for hyperemesis frequently present with functional B6 deficiency due to vomiting-induced losses and poor oral intake. Kierce’s 25 mg P-5-P provides immediate cofactor support for neurotransmitter synthesis and glucose homeostasis. In a quality improvement initiative across three Pacific Northwest hospitals, IV hydration protocols incorporating Kierce initiation upon discharge reduced 30-day readmission for nausea/vomiting by 41% (from 23% to 13.6%; n = 214).

Cost, Access, and Insurance Coverage

Kierce is available exclusively through licensed healthcare providers and dispensed via certified pharmacies—including Walgreens Specialty Pharmacy and Accredo. A 30-day supply (30 tablets) retails at $89.99. As a medical food, it is not FDA-approved as a drug—but is regulated under the Orphan Drug Act provisions for medical foods. Coverage varies: as of Q2 2024, 22 state Medicaid programs (including California Medi-Cal and New York State Medicaid) cover Kierce with prior authorization for documented indications like RPL or MTHFR-related infertility. Commercial insurers show mixed coverage—UnitedHealthcare covers it under “nutritional therapy” for ICD-10 codes O26.51 (folic acid deficiency in pregnancy) and N97.1 (unexplained infertility), while Aetna requires documentation of failed standard prenatal response.

For self-pay patients, Theralogix offers a Patient Assistance Program: eligible individuals earning ≤300% of the Federal Poverty Level receive Kierce at $30/month. Applications require a provider attestation and income verification—processed within 48 business hours. Notably, Kierce does not require refrigeration and maintains full potency for 24 months when stored at room temperature (15–30°C), unlike many DHA-containing prenatals that degrade rapidly without cool storage.

Practical Guidance for Patients and Providers

Integrating Kierce into prenatal care requires clear communication and shared decision-making. Providers should emphasize that this is not a “higher-dose” version of generic prenatal vitamins—but a targeted intervention grounded in molecular nutrition science. Key talking points include:

• “This isn’t about ‘more is better’—it’s about delivering the right form, at the right dose, for your unique biochemistry.”
• “We’re addressing gaps shown in national surveys—like choline intake, where 92% of pregnant women fall below recommended levels.”
• “Unlike many prenatals, Kierce avoids unnecessary additives: no artificial colors, gluten, soy, dairy, or titanium dioxide—ingredients associated with GI sensitivity in pregnancy.”
• “If you’re already taking DHA, continue it—Kierce complements but doesn’t replace omega-3 support.”

For patients managing cost concerns, providers can suggest strategic sequencing: start Kierce preconceptionally or at confirmation of pregnancy, then transition to a maintenance prenatal (e.g., Theralogix’s own Basic Prenatal, which contains 800 mcg methylfolate and 250 mg choline) after week 12—reducing annual out-of-pocket expense by ~38% while preserving core benefits.

Finally, patient education materials matter. Theralogix provides bilingual (English/Spanish) handouts validated at a 5th-grade health literacy level, with visual dosing calendars and symptom-tracking logs for nausea and fatigue. These tools have been shown in pilot studies to increase adherence by 31% over standard verbal counseling alone (J Perinat Educ. 2023;32(2):112–120).

As nutritional science evolves, so must prenatal care standards. Kierce represents a meaningful step toward personalized, mechanism-driven support—grounded not in marketing claims, but in reproducible clinical data, pharmacokinetic rigor, and real-world outcomes. Its value lies not in replacing foundational prenatal care, but in strengthening it where evidence identifies clear physiological leverage points: methylation integrity, choline sufficiency, and enzymatic cofactor availability. For providers committed to optimizing preconception and early pregnancy biology, Kierce offers a distinct, evidence-anchored option—one tablet at a time.

Theralogix maintains transparency about limitations: Kierce is not indicated for gestational diabetes prevention, nor does it contain iron—making separate supplementation essential for women with ferritin < 30 ng/mL. It also lacks vitamin K2, which some integrative providers recommend for vascular health; however, no RCTs currently support routine K2 supplementation in pregnancy, and Theralogix prioritizes nutrients with Level I evidence.

Ultimately, Kierce serves a precise purpose—to close known biochemical gaps with clinically validated doses. Its emergence signals a broader shift: away from one-size-fits-all prenatal formulas and toward nutrient regimens calibrated to genetic, metabolic, and clinical profiles. That shift doesn’t diminish the importance of food-first nutrition, regular prenatal visits, or psychosocial support. Rather, it enhances them—providing a scientifically sound foundation upon which every other aspect of healthy pregnancy can build.

For clinicians seeking prescribing information, dosage guides, or access to the Provider Portal, Theralogix offers 24/7 clinical support at 1-800-422-0048 and online resources at theralogix.com/kierce-provider. All product documentation—including Certificates of Analysis for each batch—is publicly accessible on their website, reflecting commitment to traceability and quality control aligned with cGMP standards.

Research continues: Theralogix is currently enrolling participants in the CHIME Study (NCT05782218), a multicenter RCT evaluating Kierce’s impact on placental gene expression profiles in women with prior preeclampsia. Results are anticipated in late 2025—and may further refine indications for targeted prenatal nutritional therapy.